Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 9 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
The Rockefeller University has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 9 examiners and 8 art units, showing a broad biotechnology prosecution footprint with examiner and art-unit concentration.
ALLEN, MICHAEL D is the busiest listed examiner, with 2 pending matters. Counsel should use the repeated examiner assignment to monitor related prosecution issues, while organizing the remaining matters by art unit and examiner for targeted responses.
The portfolio calls for centralized docket control and a consistent technical vocabulary, but not a uniform response. Differences among the examination assignments may require separate claim amendments, evidence, and interview plans.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (30%) |
| §112 only | 2 (20%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEN, MICHAEL D | 2 | 31.9% | +48.8% |
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| GUSSOW, ANNE | 1 | 57.9% | +43.8% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
| ARIETI, RUTH SOPHIA | 1 | 46.2% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18902455 | COMPOSITIONS AND METHODS FOR PRODUCING HAIR FOLLICLE STEM CELLS | MARTIN, PAUL C | — |
| 18762178 | HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120 | ALLEN, MICHAEL D | — |
| 18558066 | NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF | AEDER, SEAN E | — |
| 18340008 | HIV VACCINE IMMUNOGENS | ALLEN, MICHAEL D | — |
| 17928424 | METHOD AND SYSTEM FOR RNA ISOLATION FROM SELF-COLLECTED AND SMALL VOLUME SAMPLES | GUSSOW, ANNE | — |
| 17994090 | MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18902455 | COMPOSITIONS AND METHODS FOR PRODUCING HAIR FOLLICLE STEM CELLS | MARTIN, PAUL C | — |
| 18762178 | HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120 | ALLEN, MICHAEL D | — |
| 18558066 | NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF | AEDER, SEAN E | — |
| 18340008 | HIV VACCINE IMMUNOGENS | ALLEN, MICHAEL D | — |
| 17928424 | METHOD AND SYSTEM FOR RNA ISOLATION FROM SELF-COLLECTED AND SMALL VOLUME SAMPLES | GUSSOW, ANNE | — |
| 17994090 | MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES | GOLDBERG, JEANINE ANNE | — |
| 17794724 | PHASE SEPARATION SENSORS AND USES THEREOF | DEBERRY, REGINA M | — |
| 17503928 | CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | LEITH, NANCY J | — |
| Art Unit | Apps |
|---|---|
| 1671 | 2 |
| 1653 | 1 |
| 1672 | 1 |
| 1642 | 1 |
| 1683 | 1 |
| 1682 | 1 |
| 1647 | 1 |
| 1636 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18902455 | COMPOSITIONS AND METHODS FOR PRODUCING HAIR FOLLICLE STEM CELLS | MARTIN, PAUL C | 1653 | §102§112 | Non-Final OA | — | Pending | Sep 30, 2024 |
| 18833645 | BROADLY NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIES TARGETING THE N-TERMINAL DOMAIN OF THE SPIKE PROTEIN AND METHODS OF USE THEREOF | ALAM, DANYAL HASSAN | 1672 | §112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18762178 | HIGHLY ACTIVE AGONISTIC CD4 BINDING SITE ANTI-HIV ANTIBODIES (HAADS) COMPRISING MODIFIED CDRH2 REGIONS THAT IMPROVE CONTACT WITH GP120 | ALLEN, MICHAEL D | 1671 | §101§112DP | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18558066 | NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF | AEDER, SEAN E | 1642 | §101§112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18340008 | HIV VACCINE IMMUNOGENS | ALLEN, MICHAEL D | 1671 | §102§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 17928424 | METHOD AND SYSTEM FOR RNA ISOLATION FROM SELF-COLLECTED AND SMALL VOLUME SAMPLES | GUSSOW, ANNE | 1683 | §102§103§112 | Final Rejection | — | Pending | Nov 29, 2022 |
| 17994090 | MARKERS AND CELLULAR ANTECEDENTS OF RHEUMATOID ARTHRITIS FLARES | GOLDBERG, JEANINE ANNE | 1682 | §101§102§112Other | Non-Final OA | — | Pending | Nov 25, 2022 |
| 17794724 | PHASE SEPARATION SENSORS AND USES THEREOF | DEBERRY, REGINA M | 1647 | §112 | Final Rejection | — | Pending | Jul 22, 2022 |
| 17503928 | CRISPR-CAS COMPONENT SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | LEITH, NANCY J | 1636 | DP | Non-Final OA | — | Pending | Oct 18, 2021 |
| 17442790 | FOCUSED ULTRASOUND FOR NON-INVASIVE FOCAL GENE DELIVERY TO THE MAMMALIAN BRAIN | ARIETI, RUTH SOPHIA | 1635 | §103§112DP | Final Rejection | — | Pending | Sep 24, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Rockefeller University has 10 pending office actions as of October 2026, spread across 9 art units and 9 examiners.
Michael D Allen has the most, with 2 of The Rockefeller University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
